With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment and strong uptake of artificial intelligence technologies. The benchmark S&P ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and ...

Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...